Xenazine (tetrabenazine tablets, from Prestwick) has been FDA approved for the treatment of chorea associated with Huntington’s disease (HD). This approval was based on results from a double-blind, placebo-controlled study which found that Xenazine significantly reduced patients’ chorea burden and improved global outcome scores.

Xenazine, a monoamine depletor, is expected to be available in 2008 in 12.5mg and 25mg dosage strengths.

For more information call (202) 296-1400 or visit www.prestwickpharma.com.